PMID- 27374101
OWN - NLM
STAT- MEDLINE
DCOM- 20180326
LR  - 20220410
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 22
DP  - 2017 May 30
TI  - Circulating tumor cells (CTCs) are associated with abnormalities in peripheral 
      blood dendritic cells in patients with inflammatory breast cancer.
PG  - 35656-35668
LID - 10.18632/oncotarget.10290 [doi]
AB  - CTCs are involved in tumor dissemination and are an independent prognostic factor 
      in primary and metastatic breast cancer patients. Dendritic cells (DCs) are the 
      most efficient antigen presenting cells and are comprised of plasmacytoid-(pDC) 
      and myeloid-(mDC) derived DC subsets. This study aimed to correlate CTC counts 
      with the peripheral blood DC immunophenotypes and functions of inflammatory 
      breast cancer (IBC) patients. This study included 65 IBC patients. Peripheral 
      blood (PB) was obtained from patients prior to starting a new line of 
      chemotherapy for CTCs enumeration by CellSearch(R) and DC phenotype and function by 
      flow cytometry; the characteristics of DCs were then correlated with CTC counts 
      and clinical outcome. Twenty-one (32.3%) patients with CTCs >/=5 had a 
      significantly inferior overall survival (OS) compared to patients with <5 CTCs 
      (p=0.045). In addition, patients with >/=5 CTCs had a lower percentage of mDCs 
      capable of producing TNF-alpha before or after activation through the toll-like 
      receptor (TLR), as well as a lower percentage of mDCs producing IL-12 after 
      TLR-activation. There was a positive correlation between CTCs counts and 
      expression of the activation (CCR7) and costimulatory (CD86) receptors on 
      TLR-activated mDCs and pDCs, respectively. Moreover, presence of high percentage 
      of mDC capable to produce increased levels of TNF-alpha was independently associated 
      with inferior OS (p = 0.0006). An increase in the percentage of mDC producing 
      TNF-alpha might induce a pro-inflammatory environment that could play a role in 
      determining the poor clinical outcome in IBC patients and could add further 
      prognostic value to CTCs.
FAU - Mego, Michal
AU  - Mego M
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Currently at Department of Medical Oncology, Comenius University, School of 
      Medicine, National Cancer Institute, Bratislava, Slovakia.
FAU - Gao, Hui
AU  - Gao H
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Cohen, Evan N
AU  - Cohen EN
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Anfossi, Simone
AU  - Anfossi S
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Giordano, Antonio
AU  - Giordano A
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Currently at Department of Medicine at Medical University of South Carolina, 
      Charleston, SC, USA.
FAU - Tin, Sanda
AU  - Tin S
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Fouad, Tamer M
AU  - Fouad TM
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
AD  - Currently at Department of Medical Oncology, The National Cancer Institute, Cairo 
      University, Cairo, Egypt.
FAU - De Giorgi, Ugo
AU  - De Giorgi U
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Currently at Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la 
      Cura dei Tumori (IRST) - IRCCS, Meldola (FC), Italy.
FAU - Giuliano, Mario
AU  - Giuliano M
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Currently at Department of Clinical Medicine and Surgery, University Federico II, 
      Naples, Italy.
FAU - Woodward, Wendy A
AU  - Woodward WA
AD  - Department of Radiation Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
AD  - Department of MD Anderson Morgan Welch Inflammatory Breast Cancer Research 
      Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Alvarez, Ricardo H
AU  - Alvarez RH
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
AD  - Department of MD Anderson Morgan Welch Inflammatory Breast Cancer Research 
      Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Valero, Vicente
AU  - Valero V
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
AD  - Department of MD Anderson Morgan Welch Inflammatory Breast Cancer Research 
      Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Ueno, Naoto T
AU  - Ueno NT
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
AD  - Department of MD Anderson Morgan Welch Inflammatory Breast Cancer Research 
      Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
FAU - Hortobagyi, Gabriel N
AU  - Hortobagyi GN
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
FAU - Cristofanilli, Massimo
AU  - Cristofanilli M
AD  - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, TX, USA.
AD  - Currently at Division of Hematology-Oncology at Northwestern University Feinberg 
      School of Medicine, Northwestern University, Chicago, IL, USA.
FAU - Reuben, James M
AU  - Reuben JM
AD  - Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
AD  - Department of MD Anderson Morgan Welch Inflammatory Breast Cancer Research 
      Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, 
      TX, USA.
LA  - eng
GR  - R01 CA138239/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Cytokines)
RN  - 0 (Receptors, Chemokine)
SB  - IM
MH  - Adaptive Immunity
MH  - Adult
MH  - Aged
MH  - Cell Count
MH  - Cytokines/metabolism
MH  - Dendritic Cells/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunity, Innate
MH  - Inflammatory Breast Neoplasms/*immunology/mortality/*pathology
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Neoplastic Cells, Circulating/*pathology
MH  - Prognosis
MH  - Receptors, Chemokine/metabolism
MH  - Survival Analysis
PMC - PMC5482606
OTO - NOTNLM
OT  - adaptive immunity
OT  - circulating tumors cells
OT  - dendritic cells
OT  - inflammatory breast cancer
OT  - innate immunity
COIS- CONFLICTS OF INTEREST The authors declare no competing financial and 
      non-financial interests in relation to the work described in the manuscript.
EDAT- 2016/07/05 06:00
MHDA- 2018/03/27 06:00
PMCR- 2017/05/30
CRDT- 2016/07/05 06:00
PHST- 2016/03/29 00:00 [received]
PHST- 2016/05/13 00:00 [accepted]
PHST- 2016/07/05 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
PHST- 2016/07/05 06:00 [entrez]
PHST- 2017/05/30 00:00 [pmc-release]
AID - 10290 [pii]
AID - 10.18632/oncotarget.10290 [doi]
PST - ppublish
SO  - Oncotarget. 2017 May 30;8(22):35656-35668. doi: 10.18632/oncotarget.10290.